Protocol Ledger

NCT07388680 · Phase II/III · RECRUITING

Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia

Interventional Phase II/III clinical trial protocol NCT07388680 sponsored by Beijing Continent Pharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-26 Enrollment: 298 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07388680
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)298 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07388680
Protocol FieldVerified Registry Value
NCT IdentifierNCT07388680
Consolidated Lead SponsorBeijing Continent Pharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment298 participants (ESTIMATED)
Registered Start Date2026-03-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI